Literature DB >> 11436080

The effects of extremely low shear stress on cellular proliferation and neointimal thickening in the failing bypass graft.

S L Meyerson1, C L Skelly, M A Curi, U M Shakur, J E Vosicky, S Glagov, L B Schwartz, T Christen, G Gabbiani.   

Abstract

OBJECTIVE: Previous studies demonstrating a correlation between low shear stress (tau = 5-15 dyne/cm(2)) and experimental vein graft neointimal thickening (NIT) support the role of low tau in vein graft failure. However, a simple linear relationship between low tau and NIT would underestimate the degree of NIT evident in high-grade occlusive lesions of failing human vein grafts. In this study we used a new experimental model that maintains patency at low tau (< 2 dyne/cm(2)), to delineate possible deviations from linearity in the low tau --> NIT hypothesis.
METHODS: Thirty-two New Zealand White rabbits underwent creation of a common carotid vein patch with a segment of ipsilateral external jugular vein. Very low tau was created in 13 patches by ligation of the distal common carotid artery, leaving the only outflow through a small muscular branch. Normal tau was created in 11 patches by leaving the common carotid artery outflow intact. High tau was created in eight patches by ligation of the contralateral common carotid artery. Six patches were harvested after 2 weeks for measurement of cell cycle entry by proliferating cell nuclear antigen (PCNA) immunohistochemistry. The remaining 26 patches were harvested after 4 weeks, perfusion fixed, and excised for morphometric analysis.
RESULTS: Mean blood flow and tau at implantation ranged from 0.5 to 41 mL/min and 0.07 to 15 dyne/cm(2), respectively. At the time of harvest, 30 of 32 patches remained patent, and the artificially created aberrations in blood flow were maintained (range, 0.7-41 mL/min). After 2 weeks PCNA immunohistochemistry showed a significantly higher level of cell cycling in patches exposed to low tau (40 +/- 5 vs 1.6 +/- 0.3 PCNA-positive cells per high-power field; P <.001), which is equivalent to approximately 20% of the total cells present. In patches harvested after 4 weeks, NIT ranged from 42 to 328 microm and significantly correlated with mean tau at implantation. Patches with very low tau exhibited histologic characteristics similar to those of failing human bypass grafts, including laminar thrombus and flow-limiting luminal stenosis. The relationship between tau and NIT was nonlinear in that extremely low tau (< 2 dyne/cm(2)) resulted in NIT beyond that predicted by a simple linear correlation (P =.003).
CONCLUSION: Extremely low tau (< 2 dyne/cm(2)) stimulates high rates of smooth muscle cellular proliferation in arterialized vein patches. NIT is accelerated in these regions of low tau far beyond that predicted by a simple linear model. The nonlinear nature of the cellular proliferative response and NIT at tau less than 2 dyne/cm(2) may explain the rapid progression of neointimal lesions in failing bypass grafts.

Entities:  

Mesh:

Year:  2001        PMID: 11436080     DOI: 10.1067/mva.2001.114819

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  29 in total

1.  Hypoxia-induced phenotypic switch of fibroblasts to myofibroblasts through a matrix metalloproteinase 2/tissue inhibitor of metalloproteinase-mediated pathway: implications for venous neointimal hyperplasia in hemodialysis access.

Authors:  Sanjay Misra; Alex A Fu; Khamal D Misra; Uday M Shergill; Edward B Leof; Debabrata Mukhopadhyay
Journal:  J Vasc Interv Radiol       Date:  2010-06       Impact factor: 3.464

2.  Pathology of drug-eluting versus bare-metal stents in saphenous vein bypass graft lesions.

Authors:  Saami K Yazdani; Andrew Farb; Masataka Nakano; Marc Vorpahl; Elena Ladich; Aloke V Finn; Frank D Kolodgie; Renu Virmani
Journal:  JACC Cardiovasc Interv       Date:  2012-06       Impact factor: 11.195

3.  Hemodynamically driven vein graft remodeling: a systems biology approach.

Authors:  Scott A Berceli; Roger Tran-Son-Tay; Marc Garbey; Zhihua Jiang
Journal:  Vascular       Date:  2009 May-Jun       Impact factor: 1.285

4.  Evaluation of the hemodynamics in straight 6-mm and tapered 6- to 8-mm grafts as upper arm hemodialysis vascular access.

Authors:  M Sarmast; H Niroomand-Oscuii; F Ghalichi; E Samiei
Journal:  Med Biol Eng Comput       Date:  2014-08-12       Impact factor: 2.602

Review 5.  Current understanding of intimal hyperplasia and effect of compliance in synthetic small diameter vascular grafts.

Authors:  YeJin Jeong; Yuan Yao; Evelyn K F Yim
Journal:  Biomater Sci       Date:  2020-07-09       Impact factor: 6.843

6.  Polyester vascular patches acquire arterial or venous identity depending on their environment.

Authors:  Hualong Bai; Haidi Hu; Jianming Guo; Maryam Ige; Tun Wang; Toshihiko Isaji; Tambudzai Kudze; Haiyang Liu; Bogdan Yatsula; Takuya Hashimoto; Ying Xing; Alan Dardik
Journal:  J Biomed Mater Res A       Date:  2017-09-26       Impact factor: 4.396

7.  An early study on the mechanisms that allow tissue-engineered vascular grafts to resist intimal hyperplasia.

Authors:  Heather L Prichard; Roberto J Manson; Louis DiBernardo; Laura E Niklason; Jeffrey H Lawson; Shannon L M Dahl
Journal:  J Cardiovasc Transl Res       Date:  2011-07-12       Impact factor: 4.132

Review 8.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

9.  Hemodynamic Influence on Smooth Muscle Cell Kinetics and Phenotype During Early Vein Graft Adaptation.

Authors:  Benjamin Klein; Anthony Destephens; Leanne Dumeny; Qiongyao Hu; Yong He; Kerri O'Malley; Zhihua Jiang; Roger Tran-Son-Tay; Scott Berceli
Journal:  Ann Biomed Eng       Date:  2016-09-13       Impact factor: 3.934

Review 10.  Adaptive changes in autogenous vein grafts for arterial reconstruction: clinical implications.

Authors:  Christopher D Owens
Journal:  J Vasc Surg       Date:  2009-10-17       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.